Skip to content

D&A at other companies

Opko Health logo
Opko HealthOPK
$18.97M-4.5%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$67.15M-44.2%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Segments

By segment

See full
Domestic Operations$1.48M+4.6%
International Operations$97K-9.3%

Other financials

Income statement

See full
Revenue$71.4M-7.5%
Gross profit$21.2M-11.6%
Operating income$5.2M-38.6%
Net income$3.4M-30.1%
EPS (diluted)$1.13-30.7%

Balance sheet

See full
Cash & equivalents$10.0M-42.0%
Total debt$25.3M+6.6%
Total equity$74.7M+15.9%
Total assets$178.3M-8.4%

Cash flow

See full
Operating cash flow$5.5M-42.0%
CapEx$928.0K+79.8%
Free cash flow$4.5M-49.0%

Valuation

See full
Market cap$101.96M-32.7%
Enterprise value$117.3M-26.0%
P/E10.6×-2.7×
P/S0.4×-0.3×

Profitability

See full
Gross margin28.5%-0.1pp
Operating margin5.9%-1.5pp
Net margin3.4%-1.3pp
FCF margin5.2%

Returns & leverage

See full
Return on equity13.8%-5.3pp
Debt / equity0.3×0.0×
Current ratio2.2×0.0×

Where this comes from

Reported directly by Kewaunee Scientific Corporation in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Kewaunee Scientific Corporation’s 10-K, filed June 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kewaunee Scientific Corporation's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kewaunee Scientific Corporation's D&A?
Kewaunee Scientific Corporation (KEQU) reported D&A of $1.57M in Q1 2026.
How has Kewaunee Scientific Corporation's D&A changed year-over-year?
Kewaunee Scientific Corporation's D&A increased by 32.0% year-over-year, from $1.19M to $1.57M.
What is the long-term trend for Kewaunee Scientific Corporation's D&A?
Over 2 years (2024 to 2026), Kewaunee Scientific Corporation's D&A has grown at a 41.8% compound annual growth rate (CAGR), from $3.13M to $6.28M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.